LENZ Therapeutics (LENZ) Accumulated Expenses (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Accumulated Expenses data on file, last reported at $14.9 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $14.9 million, up 203.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.9 million (up 203.12% YoY), and the FY2025 annual result was $17.0 million, up 176.79% from the prior year.
• Accumulated Expenses retreated to $14.9 million in Q1 2026 per LENZ's latest filing, from $17.0 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $17.0 million in Q4 2025 and troughed at $882000.0 in Q2 2022.
• A 5-year average of $6.8 million and a median of $4.9 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2025: Accumulated Expenses soared 1015.33% in 2022, then sank 58.25% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $1.9 million in 2022, then soared by 584.29% to $12.8 million in 2023, then tumbled by 51.97% to $6.1 million in 2024, then jumped by 176.79% to $17.0 million in 2025, then dropped by 12.59% to $14.9 million in 2026.
• Business Quant data shows LENZ's Accumulated Expenses at $14.9 million in Q1 2026, $17.0 million in Q4 2025, and $12.0 million in Q3 2025.